Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03:00p JOHNSON & JOHNSON : U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sN..
10:17a DXB ENTERTAINMENTS : DDB Dubai names new managing director
06/27 JOHNSON & JOHNSON : Personalized nutrition co DayTwo raises $12m
06/26 JOHNSON & JOHNSON : Advanced sterilization products receives fda clearance for w..
06/26 JOHNSON & JOHNSON : Breakfast Technical Briefing on Drug Makers Stocks -- Pfizer..
06/26 JOHNSON & JOHNSON : Releases 2016 Health for Humanity Report
06/26 JOHNSON & JOHNSON : Trump picks sports billionaire as new US ambassador to Brita..
06/24 JOHNSON & JOHNSON : American Dental Hygienists' Association Honors Dental Hygien..
06/24 DXB ENTERTAINMENTS : DDB Dubai appoints Iris Minnema as MD
06/23 JOHNSON & JOHNSON : State investigates drug makers
More news
Sector news : Pharmaceuticals - NEC
06:52p UK blue chips led lower by Hargreaves as strong pound takes toll
06:40pDJVECTURA : In Asthma Collaboration With Novartis's Sandoz
05:33pDJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
08:35a Factbox - Companies hit by global ransomware attack on June 27
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:01p Globus Medical Has Wobbled A Bit, But Still On Good Footing
08:44a FDA grants Priority Review status for lower dose of J&J's Xarelto
06/27 TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
06/27 Kala Pharmaceuticals Files For $86 Million IPO
06/27 GOLDMAN SACHS GROUP : Fair Total Return For This Investment Bank
Advertisement
Financials ($)
Sales 2017 75 604 M
EBIT 2017 23 480 M
Net income 2017 17 895 M
Debt 2017 8 106 M
Yield 2017 2,49%
P/E ratio 2017 20,59
P/E ratio 2018 18,50
EV / Sales 2017 4,92x
EV / Sales 2018 4,68x
Capitalization 363 694 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 132 $
Spread / Average Target -2,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
SANOFI13.95%125 371
More Results